In a recent case report published in the Journal of Clinical Laboratory Analysis, researchers presented two cases to highlight the impact of cold agglutinin syndrome (CAS) on clinical presentations in ...

During a discussion on the next frontier of medicine for cold agglutinin disease, stakeholders react to the rationale for studying newer, novel complement-targeted therapies. Neil Minkoff, MD: Let me ...

A new drug has become the first and only treatment for people with cold agglutinin disease (CAD) that is approved by the US Food and Drug Administration (FDA). The new product is sutimlimab-jome ...

What are the symptoms for cold agglutinin disease, and how is it diagnosed? -- P.W. ANSWER: Cold agglutinin disease is a specific type of anemia where antibodies attack and destroy a person’s own red ...

Enjaymo is an immunoglobulin G subclass 4 monoclonal antibody. The Food and Drug Administration (FDA) has expanded the approval of Enjaymo ® (sutimlimab-jome) for the treatment of hemolysis in adults ...

Mihir Raval, MD, MPH, comments on the difference between cold agglutinin disease and other autoimmune hemolytic anemias. Neil Minkoff, MD: Now, you had mentioned that there are other autoimmune ...

(RTTNews) - Sanofi (SNYNF, SNY) said that the U.S. Food and Drug Administration has approved Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults ...

Antibodies are disease-fighting proteins that play a crucial role in the immune system. Antibodies recognize infectious invaders, such as bacteria and viruses, and help the body eliminate them.